NKN.L. Kostina

N.L. Kostina

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


N.L. Kostina has a total of 10 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • In-hospital and post-hospital serum high-sensitivity and monomeric C-reactive protein in patients with acute ST segment elevation myocardial infarction and previous COVID-19

    by V.P. Mikhin, A.I. Gindler, I.S. Melnikov, O.S. Saburova, Z.A. Gabbasov, T.A. Nikolenko, M.A. Chernyatina, N.L. Kostina, L.S. Maltseva, S.A. Boytsov

    Objective. To analyze in-hospital and post-hospital (up to 6 months) serum hsCRP and mCRP in patients with acute ST-segment elevation myocardial infarction (STEMI) and previous COVID-19. Material and methods. There were 140 patients with STEMI stratified into 2 groups: 1 — 52 STEMI patients with COVID-19 1.5—6 months before acute coronary syndrome (ACS), 2 — 88 patients with STEMI and no previous COVID-19. PCI with stenting of infarct-related artery was performed on the first day. Serum hsCRP and mCRP were determined in 2 and 10 days, 1 and 6 months after MI. Results. Serum mCRP was higher in the main group at all time points: by 5.09 times after 2 day, 13.50 times after 10 days, 5.70 times after 1 month and 2.41 times after 6 months. In-hospital serum hsCRP was higher in the main group (by 2.05 times after 2 days and 3.36 times after 10 days). Serum hsCRP after 1 and 6 months was equivalent in both groups. Dynamics of serum mCRP and hsCRP was multidirectional after 10 days (mCRP increased, hsCRP did not change in the main group, and both parameters decreased in the control group). After 1 and 6 months, dynamics of these parameters was unidirectional and positive in both groups. Conclusion. Patients with STEMI and previous COVID-19 are characterized by higher concentration of mCRP in the first 6 months and hsCRP in the first month of treatment. This indicates more severe inflammatory reaction in the first 6 months after STEMI.

  • The possibilities of Mexidol in the complex therapy of arterial hypertension

    by V.P. Mikhin, N.L. Kostina, T.A. Nikolenko, V.V. Savelyeva, M.A. Chernyatina

    A review of the literature is devoted to the effects of the ethylmethylhydroxypyridine succinate (mexidol) in patients with arterial hypertension. The analysis of 44 sources of Russian and foreign literature showed more effective achievement of the target values of blood pressure, prevention of severe complications in hypertensive crises in patients with mexidol therapy. The evidence of the positive effect of cytoprotective therapy on the condition of the left ventricle and vascular wall is considered. The results of large-scale studies demonstrating the effective correction of cognitive dysfunction of the brain using mexidol are presented. The role of the drug in stabilizing of biochemical processes, including lipid peroxidation, glucose and cholesterol metabolism, which determines the pleiotropic effects of mexidol in patients with hypertension, is emphasized.